Mark:

SUPER9

Status Date:

01-07-2020

Registration Number:

5953493

Goods and Services:

Medicinal preparations for treatment of hemophilia A, namely, viral systems, gene therapy systems, nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors; Viral systems, gene therapy systems, nucleic acid delivery systems for medical purposes, namely, medicines for the treatment of hemophilia A; Pharmaceutical preparations and substances for the treatment of hemophilia A; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy for the treatment of hemophilia A; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, vaccines, prophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapy, gene therapy and cell therapy for the treatment of hemophilia A

Class:

Pharmaceutical and veterinary preparations

Published for Opposition Date:

10-22-2019

Mark Drawing Status:

Standart Character Mark

Business Name:

WOMBLE BOND DICKINSON (US) LLP